Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

13.58.91.217
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Journal Scan
Rheumatology

Poor compliance linked to catastrophic progression to end-stage kidney disease in lupus nephritis

Posted on

Patients with lupus nephritis who had poor compliance and histopathologic features incluading thrombotic microangiopathy, collapsing glomerulopathy, and concomitant anti-glomerular basement membrane (anti-GBM) nephropathy were more likely to experience catastrophic progression to end-stage kidney disease (ESKD), according to a study.

This study included 10 with lupus nephritis who developed ESKD within 3 years of initial diagnosis, for a total of 1.8% of the total LN population. Researchers reviewed the pathology reports for distinct histopathologic features, as well as demographic, clinical, laboratory, and therapeutic variables.

-Advertisement-
-Advertisement-

The mean time to ESKD was 19.2 ± 12.4 months. The median rate of kidney function decline was more than 43 ml/min/1.73m2 per year.

Patients included had LN class III (n = 1), class IV (n = 5), membranous LN/class V (n = 2), and mixed IV/V (n = 2). Extensive thrombotic microangiopathy occurred in 2 patients, 1 with collapsing glomerulonephritis and 1 with concomitant anti-glomerular basement membrane (anti-GBM) nephropathy.

Severe non-compliance, which included stopping all medication to follow alternative treatments, was noted in 4 patients.

Reference
Tselios K, Gladman DD, Taheri C, et al. Factors Associated with Rapid Progression to End Stage Kidney Disease in Lupus Nephritis. J Rheumatol. 2020:jrheum.200161. DOI: 10.3899/jrheum.200161. Epub ahead of print. PMID: 33259331.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-